Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep-Oct;75(5):634-41.
doi: 10.1016/s1808-8694(15)30510-3.

Report on hearing loss in oncology

Christiane Schultz  1 , Maria Valéria Schmidt Goffi-Gomez, Patrícia Helena Pecora Liberman, André Lopes Carvalho
Affiliations

Report on hearing loss in oncology

Christiane Schultz et al. Braz J Otorhinolaryngol. 2009 Sep-Oct.

Abstract

Cisplatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m(2), ototoxicity may ensue, resulting in loss of hearing. Criteria for identifying and quantifying hearing loss have been devised.

Aim: To describe the features of different hearing loss classification systems and to identify their implications and use in oncologic patients.

Method: Hearing loss was classified in 31 patients before and after chemotherapy, according to different criteria, assessing the sensitivity and specificity of each classification system.

Results: Hearing loss results were highly variable (ranging from 29% to 61%). Only 4 of 31 subjects with post-therapy hearing loss were identified by all the methods. A few subjects with hearing loss were classified as normal hearing in some of the criteria. A normal PTA was found in 18 of 31 subjects in the post-treatment evaluation.

Conclusion: None of the criteria assesses the complaints of patients. The criteria described in this study were inadequate to identify hearing loss following chemotherapy, requiring additional information for physicians to better understand the hearing losses and their implications for the quality of life of patients.

PubMed Disclaimer

References

    1. Oliveira JAA. In: Otorrinolaringologia. Costa SS, Cruz OLM, Oliveira JAA, editors. Artes Medicas Sul; Porto Alegre: 1994. Ototoxicidade; pp. 215–221.
    1. Whitworth LP., C.A. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005;10:1313–1321. - PubMed
    1. Brock PR, Bellman SC, Yeomans EC, Pinkerton R, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295–300. - PubMed
    1. Pedalini MEB, Toniosso S, Goffi MVS. In: Fonoaudiologia em cancerologia. Barros APB, editor. Fundação Oncocentro de São Paulo; São Paulo: 2000. O papel do audiologista no tratamento do pacientes com câncer; pp. 105–109.
    1. Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002;214:149–152. - PubMed

MeSH terms